News zum Sektor Gesundheit aus Schweden

 

Leslie Bibb, John Mayer, Amaury Guichon and a Host of Cultural Tastemakers Came Together for an Evening Celebrating Personal Style, Design and the Newest LG SIGNATURE Collections News Summary: LG SIGNATURE held an exclusive celebration at New York City's Solomon R. Guggenheim Museum,......

Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management......

Uppsala, October 12, 2026 – Elicera Therapeutics AB (publ) today announces that the Phase I part of the CARMA study has been completed. The study is evaluating the safety and preliminary efficacy of escalating doses of ELC-301, Elicera's iTANK-armed CAR T-cell therapy, in patients with B-cell lymphoma who have no remaining curative treatment options. Eight of twelve patients achieved complete metabolic response (CMR), meaning no active disease, as their best response during the follow-up. Objective tumor response, i.e. a reduction in tumor burden, was observed in eleven patients. Six patients...

LUND, SE / ACCESS Newswire / October 12, 2026 / BioInvent International AB ("BioInvent") (STO:BINV), a leader in the discovery of novel immunomodulatory antibodies, today announced that the company......

Lund, Sweden — 12 October 2026 — Camurus (NASDAQ STO: CAMX) today announced that Health Canada has issued a Notice of Compliance (NOC) for Oczyesa[®] XR, octreotide subcutaneous depot, for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.[1] "Oczyesa XR offers people with acromegaly sustained control of their disease with a once-monthly injection they can take themselves, at home, instead of relying on clinic visits. We look forward to the launch of Oczyesa XR in Canada and to making it available to patients",...

The shareholders of Episurf Medical AB (publ), reg. no. 556767-0541 ("Episurf" or the "Company"), are hereby given notice to attend the Extraordinary General Meeting to be held on Thursday, 12 November 2026, at 15:00 (CET) at Episurf's office at Karlavägen 60, SE-114 49 Stockholm, Sweden. The entrance opens at 14:30 (CET). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company's articles of association, resolved that shareholders shall be able to exercise their voting rights by post prior to the...

The Board of Directors of Episurf Medical AB (publ) ("Episurf", or the "Company") has taken note of a press release published by Ilija Batljan Invest AB (publ), reg. no 559053-5166 ("IBI") on 9 October 2026, according to which IBI intends to make an offer to repurchase all bonds issued by IBI with ISIN SE0016101810 (the "Bonds") in return for a cash payment equivalent to 100 percent of the outstanding nominal amount of the Bonds, together with accrued and unpaid interest in accordance with the terms and conditions of the Bonds, subject to the condition that bondholders who accept the offer...

MALMÖ, SE / ACCESS Newswire / October 11, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) today announces that it has received the official minutes from its Type A meeting with the U.S. ......

BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2026 will be published at approximately 8:00 AM CEST on October 22, 2026. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. Join the audiocast/teleconference: Audiocast: https:...

Peptonic Medical AB (publ) ("Peptonic" or the "Company") today provides an update on the Company's product development, the commercial progress of its partnership with US-based Joylux Inc. ("Joylux"), and its efforts to broaden VagiVital into a stronger offering within women's health and well-being. Several new products will be introduced during the autumn, including the Company's first dietary supplement, while the partnership with Joylux continues to develop in the North American market. During 2026, Peptonic has carried out extensive work to broaden its product portfolio and establish a...

Perpetua Medical AB (publ) (“Perpetua Medical” or the “Company”) announces that Thomas Pousette has left the Company's management team for personal reasons. The change takes effect immediately. Following this change, Perpetua Medical's management team consists of Anders Hedlund, CEO, and Camilla Lönn, CFO. The information was submitted for publication, through the agency of the contact person set out below, on October 9, 2026, at 8 AM CEST.   For further information Please contact: Anders Hedlund, CEO, tel: +46 18 71 13 32 or via email: anders.hedlund@perpetuamedical.se...

GOTHENBURG, SE / ACCESS Newswire / October 9, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced th......

New insights into the mechanism of action of the anti-cancer drug Alpha1H are published today in Molecular Therapy, a Cell Press journal. The study maps how Alpha1H disrupts the adhesive structures that hold malignant cells together in the tumor and anchor the tumor to the underlying tissue. By targeting adhesion, Alpha1H disrupts the tumor structure, in addition to killing the tumor cells. The findings explain the massive tumor cell shedding observed in treated patients and strengthen the scientific basis for Hamlet BioPharma's bladder cancer program, with patients now being treated in Phase...

October 8th  2026 CHOSA Oncology AB announces that it has received 94 tumour biopsy samples from Mount Sinai Hospital in New York as part of its ongoing research collaboration to evaluate the ability of Platin-DRP® to identify patients with advanced non-small cell lung cancer (NSCLC) who are most likely to benefit from platinum-based chemotherapy combined with immunotherapy. The samples represent patients treated with platinum chemotherapy in combination with a PD-1/PD-L1 inhibitors like Keytruda and Opdivo. The tumour samples will undergo RNA analysis at CHOSA's laboratory partner, after...

STOCKHOLM, SE / ACCESS Newswire / October 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disea......

Arjo will issue its interim report for Q3 on Thursday October 22 at 07:00 CEST, followed by a conference call at 08:00, hosted by Andréas Elgaard, President and CEO, and Christofer Carlsson, CFO. Fund managers, analysts and media are invited to participate in a conference call and presentation of the report via the following link (https://events.inderes.com/arjo/q3-report-2026) and a recorded version of the conference is accessible for three years here (https://events.inderes.com/arjo/q3-report-2026). Those who wish to ask questions verbally in the teleconference will need to register...

On 1 October 2026, Episurf Medical AB (publ) ("Episurf") issued, in relation to the closing of the acquisition of the Hudiksvall portfolio, convertibles in an aggregated nominal amount of SEK 64,780,000. Convertibles in a nominal amount of SEK 9,279,911 have, as of the date of this press release, at the request from holders of convertible debentures, been converted into 206,220,244 Class B shares in Episurf at a conversion price of SEK 0.045 per share in accordance with the terms and conditions. Through the conversion, the number of Class B shares and votes in Episurf increases by 206,...

Qlife Holding AB (the “Company” or “Qlife”) held an Extraordinary General Meeting on 7 October 2026, at which the following resolutions were adopted. Resolution on change of auditor It was resolved, in accordance with the proposal of the board of directors, to appoint the registered audit firm Grant Thornton Sweden AB (“Grant Thornton”) as auditor of the Company. Grant Thornton has informed that the authorised public accountant Mattias Olofson will continue to serve as auditor-in-charge for the period until the end of the next annual general meeting. __________ For further...

Ambea, a leading Nordic care provider, and AGE-WELL, Canada's technology and aging network, have formed a strategic partnership to accelerate the development and adoption of innovative care solutions. By combining Canadian research and technology expertise with Nordic care experience, the partnership aims to improve quality of life for older adults and provide better support for care professionals. A growing older population is increasing demand for care and new ways of working. At the same time, advances in AI, digitalisation and care technologies are creating new opportunities to improve...